Phaseline

Targets › SLC22A8

SLC22A8 (Organic anion transporter 3): drug programs, companies and trials

4 programs from 4 companies in 5 trials: 3 Phase 2, 1 Phase 3, 1 Phase 1; Neurology, Oncology, Psychiatry; next expected readout Dec 2026.

Functions as an organic anion/dicarboxylate exchanger that couples organic anion uptake indirectly to the sodium gradient. Transports organic anions such as estrone 3-sulfate (E1S) and urate in exchange for dicarboxylates such as glutarate or ketoglutarate (2-oxoglutarate). (UniProt, Q8TCC7)

Open in Phaseline: the race on SLC22A8, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of MiamiProbenecid
Solute carrier family 22 member 6 inhibitor; Solute carrier family 22 member 8 inhibitor; Solute carrier family 22 member 11 inhibitor
SLC22A6, SLC22A8, SLC22A11Phase 3Infertility, MaleMay 2027
Memorial Sloan Kettering Cancer CenterBusulfan
Alkylating agent; DNA cross-linking agent
SLC22A8Phase 2AML; Hematologic MalignanciesDec 2026
Fondation Ophtalmologique Adolphe de RothschildProbenecid
Solute carrier family 22 member 6 inhibitor; Solute carrier family 22 member 8 inhibitor; Solute carrier family 22 member 11 inhibitor
SLC22A6, SLC22A8, SLC22A11Phase 2Focal EpilepsySep 2029
Brown UniversityProbenecid
Solute carrier family 22 member 6 inhibitor; Solute carrier family 22 member 8 inhibitor; Solute carrier family 22 member 11 inhibitor
SLC22A6, SLC22A8, SLC22A11Phase 2Alcohol Use Disorder (AUD)Dec 2030

Conditions

Infertility, Male (1) AML (1) Hematologic Malignancies (1) Alcohol Use Disorder (AUD) (1) Focal Epilepsy (1)

Modalities

small molecule (4)

Companies

University of Miami (1) Memorial Sloan Kettering Cancer Center (1) Brown University (1) Fondation Ophtalmologique Adolphe de Rothschild (1)

Related targets

SLC22A6 (3) SLC22A11 (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.